Treatment of Giant Cell Arteritis with Acute Visual Loss or Amaurosis Fugax

Clinical Scenario

Active giant cell arteritis presenting with acute visual loss or amaurosis fugax is a sight-threatening emergency. Acute visual symptoms in this setting indicate high-risk disease activity and require an immediate, structured escalation of treatment intensity.

Treatment Approach

Management begins with high-dose intravenous corticosteroid therapy given over several days, followed by a structured oral corticosteroid regimen. The complete dosing sequence, tapering schedule, and full protocol are detailed in the evidence-based regimen below.

Treatment Goals

The aim is remission: absence of all clinical signs and symptoms attributable to active giant cell arteritis, combined with normalisation of ESR and CRP.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/annrheumdis-2019-215672

In patients with GCA with acute visual loss or amaurosis fugax, the administration of 0.25–1 g intravenous methylprednisolone for up to 3 days should be considered, because these high doses have both genomic and rapid non-genomic effects.

In patients with GCA-related visual symptoms consider a starting dose of 60 mg prednisone per day after GC administration.

We recommend tapering the GC dose in GCA to a target of 15–20 mg/day within 2–3 months and then to ≤5 mg/day after 1 year.

Absence of all clinical signs and symptoms attributable to active LVV and normalisation of ESR and CRP.

View source ↗